High-risk myelodysplastic syndromes: Chemotherapy, transplantation, and beyond

Current Hematologic Malignancy Reports

Volumn 5, Issue 1, 2010, Pages 1-8

  Gergis, Usama ^a   Wissa, Usama ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hypomethylation; Myeloablative; Myelodysplastic syndrome; Non Myeloablative; Transplant

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA METHYLTRANSFERASE; FLUDARABINE; IDARUBICIN; MELPHALAN; PROTEIN P15; PROTEIN P16; THYMOCYTE ANTIBODY; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOPENIA; DNA METHYLATION; DONOR LYMPHOCYTE INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME INHIBITION; GRAFT FAILURE; HUMAN; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; WHOLE BODY RADIATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA-CYTOSINE METHYLASES; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; TRANSPLANTATION CONDITIONING;

EID: 73549124282     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0035-0     Document Type: Review

References (51)

1. P Greenberg C Cox MM LeBeau, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088 1:CAS:528:DyaK2sXhvVars70%3D 9058730
2. L Malcovati MG Porta C Pascutto, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
3. L Malcovati U Germing A Kuendgen, et al. 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 3503 3510 10.1200/JCO.2006.08.5696 17687155 This WHO classification-based prognostic scoring system (WPSS) was able to classify patients into five risk groups showing different survivals (median survival, 12 to 103 months) and probabilities of leukemic evolution (Pubitemid 47315575)
4. D Haase U Germing J Schanz, et al. 2007 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 4385 4395 10.1182/blood-2007-03-082404 1:CAS:528:DC%2BD1cXot1Sq 17726160
5. H Kantarjian S O'Brien F Ravandi, et al. 2008 Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 1351 1361 10.1002/cncr.23697 1:CAS:528:DC%2BD1cXhtFyls7rM 18618511
6. LR Silverman EP Demakos BL Peterson, et al. 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B J Clin Oncol 20 2429 2440 10.1200/JCO.2002.04. 117 1:CAS:528:DC%2BD38XksFakur8%3D 12011120 (Pubitemid 34525728)
7. LR Silverman DR McKenzie BL Peterson, et al. 2006 Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 3895 3903 10.1200/JCO.2005.05.4346 1:CAS:528:DC%2BD28Xps1Sitrk%3D 16921040 (Pubitemid 46630737)
8. P Fenaux GJ Mufti E Hellstrom-Lindberg, et al. 2009 International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 223 232 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D 19230772
9. H Kantarjian JP Issa CS Rosenfeld, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D 16532500
10. H Kantarjian Y Oki G Garcia-Manero, et al. 2007 Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 52 57 10.1182/blood-2006-05-021162 1:CAS:528:DC%2BD2sXivVyrt7c%3D 16882708 (Pubitemid 46053042)
11. H Kantarjian M Beran J Cortes, et al. 2006 Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Cancer 106 5 1099 1109 10.1002/cncr.21699 1:CAS:528:DC%2BD28Xis1agt7w%3D 16435387 (Pubitemid 43297349)
12. H Kantarjian S O'Brien J Cortes, et al. 2006 Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 106 5 1090 1098 10.1002/cncr.21723 16435386 (Pubitemid 43297348)
13. M Oosterveld P Muus S Suciu, et al. 2002 EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors Leukemia 16 9 1615 1621 10.1038/sj.leu.2402591 1:CAS:528:DC%2BD38XmsV2lsbg%3D 12200672 (Pubitemid 35050089)
14. J Sierra WS Pérez C Rozman, et al. 2002 Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 1997 2004 1:CAS:528:DC%2BD38Xnt1yhsr0%3D 12200358
15. T De Witte J Hermans J Vossen, et al. 2000 Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 110 620 630 10.1046/j.1365-2141.2000.02200.x 10997974 (Pubitemid 30769263)
16. CS Cutler SJ Lee P Greenberg, et al. 2004 A decision analysis of allergenic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 579 585 10.1182/blood-2004-01-0338 1:CAS:528: DC%2BD2cXlvFSmsL4%3D 15039286 (Pubitemid 38900045)
17. EP Alessandrino MG Della Porta A Bacigalupo, et al. 2008 WHO classification and WPSS predict post transplant outcome in patients with myelodysplastic syndrome: a study from the GITMO (Gruppo Italiano Trapianto di Midollo Osseo) Blood 112 895 902 10.1182/blood-2008-03-143735 1:CAS:528:DC%2BD1cXpsVaisLs%3D 18497321 WPSS shows a prognostic significance for both OS and probability of relapse. In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS and were associated with increased transplant-related mortality
18. P Guardiola V Runde A Bacigalupo, et al. 2002 Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes Blood 99 4370 4378 10.1182/blood.V99.12.4370 1:CAS:528:DC%2BD38XksFGksr4%3D 12036864 (Pubitemid 34627203)
19. N Flomenberg LA Baxter-Lowe D Confer, et al. 2004 Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome Blood 104 1923 1930 10.1182/blood-2004-03-0803 1:CAS:528:DC%2BD2cXotVOqtL8%3D 15191952 (Pubitemid 39297840)
20. HJ Deeg B Storer JT Slattery, et al. 2002 Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood 100 1201 1207 10.1182/blood-2002-02-0527 1:CAS:528:DC%2BD38Xmt12it7g%3D 12149198 (Pubitemid 34864272)
21. NS Majhail CG Brunstein M Tomblyn, et al. 2008 Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor Biol Blood Marrow Transplant 14 282 289 10.1016/j.bbmt.2007.12.488 1:CAS:528:DC%2BD1cXjs1eltr4%3D 18275894 The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a compatible donor. On multivariate analysis, graft type had no impact on transplant-related mortality or survival, and the HCT comorbidity index score was the only factor independently predictive for these end points (Pubitemid 351218198)
22. JN Barker DJ Weisdorf TE DeFor, et al. 2005 Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy Blood 105 1343 1347 10.1182/blood-2004-07- 2717 1:CAS:528:DC%2BD2MXhtFCgtbs%3D 15466923 (Pubitemid 40170912)
23. ED Warlick A Cioc T Defor, et al. 2009 Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden Biol Blood Marrow Transplant 15 30 38 10.1016/j.bbmt.2008.10.012 19135940
24. BL Scott B Storer MR Loken, et al. 2005 Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Biol Blood Marrow Transplant 11 65 73 10.1016/j.bbmt.2004.10.001 15625546 (Pubitemid 40057995)
25. I Yakoub-Agha P de La Salmonière P Ribaud, et al. 2000 Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation J Clin Oncol 18 963 971 1:STN:280:DC%2BD3c7mtVOguw%3D%3D 10694545
26. K Nakai Y Kanda S Fukuhara, et al. 2005 Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome Leukemia 19 396 401 10.1038/sj.leu.2403640 1:CAS:528:DC%2BD2MXhsFOqsrg%3D 15674354 (Pubitemid 40403316)
27. H Castro-Malaspina AA Jabubowski EB Papadopoulos, et al. 2008 Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings Biol Blood Marrow Transplant 14 458 468 10.1016/j.bbmt.2008.02.006 1:CAS:528:DC%2BD1cXkslOrsL0%3D 18342789
28. MB Maris BM Sandmaier BE Storer, et al. 2006 Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing Biol Blood Marrow Transplant 12 454 465 10.1016/j.bbmt.2005.12.030 1:CAS:528:DC%2BD28XjslGnu7c%3D 16545729 (Pubitemid 43380962)
29. Field T, Perkins J, Huang Y, et al.: 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009 Jun 22 (Epub ahead of print).
30. Lübbert M, Bertz H, Rüter B, et al.: Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009 Apr 13 (Epub ahead of print).
31. De Padua Silva L, de Lima M, Kantarjian H, et al.: Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2′-deoxy-5 azacytidine for patients with myelodysplastic syndrome [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1468.
32. TJ Nevill HC Fung JD Shepherd, et al. 1998 Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation Blood 92 1910 1917 1:CAS:528: DyaK1cXmtVOhtb4%3D 9731047
33. Onida F, Brand R, van Biezen A, et al.: Impact of cytogenetics on outcome of patients with MDS or secondary AML undergoing allogeneic HSCT from HLA-identical siblings: a retrospective analysis of the EBMT-CLWP [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2653.
34. B Rüter P Wijermans R Claus, et al. 2007 Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7 Blood 110 1080 1082 10.1182/blood-2007-03-080630 17644749 (Pubitemid 47267457)
35. Kolb HJ, Schmid C, Tischer J, et al.: Allogeneic stem cell transplantation for MDS and sAML following reduced intensity conditioning and preemptive donor lymphocyte transfusion [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 324.
36. E Jabbour S Giralt H Kantarjian, et al. 2009 Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia Cancer 115 1899 1905 10.1002/cncr.24198 1:CAS:528:DC%2BD1MXlt1ygu7o%3D 19235255
37. K Rezvani AS Yong S Mielke, et al. 2008 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood 111 236 242 10.1182/blood-2007-08-108241 1:CAS:528:DC%2BD1cXjtVKiug%3D%3D 17875804
38. JE Anderson FR Appelbaum G Schoch, et al. 1996 Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors J Clin Oncol 14 220 226 1:CAS:528: DyaK28XhtVOjt7c%3D 8558201
39. B Scott HJ Deeg B Storer T Chauncey, et al. 2004 Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML Leuk Lymphoma 45 2409 2417 10.1080/10428190412331283206 1:CAS:528:DC%2BD2cXhtVKru73J 15621753 (Pubitemid 40081183)
40. H Castro-Malaspina RE Harris J Gajewski, et al. 2002 Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program Blood 99 1943 1951 10.1182/blood.V99.6.1943 1:CAS:528:DC%2BD38XitF2nt7w%3D 11877264 (Pubitemid 34525473)
41. JA Russell HT Tran D Quinlan, et al. 2002 Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 8 468 476 10.1053/bbmt.2002.v8.pm12374451 1:CAS:528:DC%2BD38Xot1Ggsrc%3D 12374451
42. M de Lima D Couriel PF Thall, et al. 2004 Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 104 857 864 10.1182/blood-2004-02-0414 15073038 (Pubitemid 38970585)
43. AY Ho A Pagliuca M Kenyon, et al. 2004 Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 104 1616 1623 10.1182/blood-2003-12-4207 1:CAS:528:DC%2BD2cXns1Okt7g%3D 15059843 (Pubitemid 39202266)
44. X Ma M Does A Raza, et al. 2007 Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 1536 1542 10.1002/cncr.22570 17345612 (Pubitemid 46595689)
45. H Wallen TA Gooley HJ Deeg, et al. 2005 Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older J Clin Oncol 23 3439 3446 10.1200/JCO.2005.05.694 15824415 (Pubitemid 46243487)
46. M de Lima A Anagnostopoulos M Munsell, et al. 2004 Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 865 872 10.1182/blood-2003-11-3750 15090449 (Pubitemid 38970586)
47. MJ Stuart TM Cao BM Sandmaier, et al. 2003 Efficacy of nonmyeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia) [abstract 644] Blood (ASH Annual Meeting Abstracts) 102 185a
48. R Martino S Iacobelli R Brand, et al. 2006 Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 836 846 10.1182/blood-2005-11-4503 1:CAS:528:DC%2BD28XnvFajtrc%3D 16597592 (Pubitemid 44154615)
49. BL Scott BM Sandmaier B Storer, et al. 2006 Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis Leukemia 20 128 135 10.1038/sj.leu.2404010 1:STN:280:DC%2BD283hvFWnuw%3D%3D 16270037
50. SJ Lee J Klein M Haagenson, et al. 2007 High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation Blood 110 4576 4583 10.1182/blood-2007-06-097386 1:CAS:528:DC%2BD1cXot1ej 17785583
51. Gergis U, Markey K, Greene J, et al.: Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2009 Aug 17 (Epub ahead of print).